Markets:

Overview

News

Currencies

International

Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

5.810 -0.230 (-3.81%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Xeris Biopharma (XERS) Q4 2025 Earnings Transcript ↗

March 02, 2026

Xeris Biopharma (XERS) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook ↗

March 02, 2026

Via Chartmill

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

March 02, 2026

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

February 26, 2026

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Outlook For Xeris Biopharma Holdings ↗

May 07, 2025

Via Benzinga

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

February 17, 2026

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

January 08, 2026

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

January 02, 2026

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗

December 31, 2025

One of the company's key drugs won't be challenged by a competing medication anytime soon.

Via The Motley Fool

The market is filled with gapping stocks in Wednesday's session. ↗

December 31, 2025

Via Chartmill

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

December 01, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗

November 06, 2025

Xeris Biopharma (XERS) Q3 2025 Earnings Transcript

Via The Motley Fool

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗

November 06, 2025

Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance.

Via Chartmill

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

November 06, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

October 23, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

August 25, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris (XERS) Q2 Revenue Jumps 49% ↗

August 07, 2025

Via The Motley Fool

Traders are paying attention to the gapping stocks in Thursday's session. ↗

August 07, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗

August 07, 2025

Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to...

Via Chartmill

Topics Earnings

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

August 07, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

July 31, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗

July 07, 2025

XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score.

Via Chartmill

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 03, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Announces Details for Analyst & Investor Day

May 20, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template ↗

May 13, 2025

XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.

Via Chartmill

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 08, 2025

From Xeris Biopharma Holdings, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.